EQS-News: Carl Zeiss Meditec with stable revenue development on a currency-adjusted basis after nine months of 2025/26

Summary by AI BETAClose X

Carl Zeiss Meditec reported revenue of €1,553.7 million for the first nine months of fiscal year 2025/26, a 2.9% decrease year-on-year, but stable at 0.0% on a currency-adjusted basis, with adjusted EBITA at €124.5 million, down from €177.0 million in the prior year, resulting in an adjusted EBITA margin of 8.0% compared to 11.1%. The Ophthalmology unit saw a revenue decline of 4.8% (2.9% adjusted) to €1,191.4 million, impacted by issues with intraocular lenses in China and softer investment in APAC, while the Microsurgery unit grew revenue by 3.8% (7.1% adjusted) to €362.3 million, driven by neurosurgical operating microscopes. The company expects full-year revenue between €2.15 billion and €2.20 billion and an adjusted EBITA margin of 8% to 10%, with plans to integrate its ophthalmic surgery business and optimize its manufacturing footprint.

Disclaimer*

UK 100

Latest directors dealings